WaveStone Capital's Catherine Allfrey warns of profit downgrades to come as downturn hits

Catherine Allfrey of WaveStone Capital will be speaking at this year's Sohn Hearts & Minds Conference in Hobart, raising funds for medical research.

Glenda Korporaal

WaveStone Capital's Catherine Allfrey warns of profit downgrades to come as downturn hits

October 17, 2022
Catherine Allfrey of WaveStone Capital will be speaking at this year's Sohn Hearts & Minds Conference in Hobart, raising funds for medical research.
Read Transcript

Investors should brace for a string of profit downgrades as the global economic downturn hits Australia somewhere between early ­December and February.

That’s the view of WaveStone Capital director Catherine Allfrey, who says that corporates are in a twilight zone between the difficult times later this year and the strong earnings from the bounce out of the Covid-19 pandemic.

“We are waiting for the profit downgrades to come through in the US and Australia,” she said in an interview with The Australian.

“Rates are going to go up and consumption is going to be hit. It’s a question of when that is going to happen. Everyone knows the slowdown is coming,” she said.

“When we ask companies when they think it is going to happen, their answers range from early December to the back-to-school period in February.”

Ms Allfrey was speaking ahead of her first appearance at the annual Sohn Hearts & Minds investment conference to be held in Hobart in November.

The Sohn conference, which sees top fund managers give their stock tips, has raised more than $40m for medical research since it began in Australia in 2016, inspired by a similar event started in New York in 1995 in memory of Wall Street fund manager Ira Sohn, who died of cancer aged 29.

Ms Allfrey says her stock tip would be in line with the investment approach at WaveStone, which she co-founded in 2006, of looking for “quality companies with a sustainable competitive ­advantage at a reasonable price”.

“We have a very tight process (of stock selection),” she says. “We are value orientated.”

WaveStone, which is 32.5 per cent owned by the ASX-listed Challenger Group, has some $5bn in funds under management, $1bn in retail investment and another $4bn invested on behalf of super fund and institutional investors.

It invests in Australian companies and they must be profitable or expect to be within 12 months. The portfolio includes Qantas, ResMed, Woodside, Santos, CSL, Carsales and Aristocrat.

In selecting her stock tip, Ms Allfrey says she will also keep in mind Sohn’s preference for talking about companies that are seen as disruptive. “I’m looking at a few candidates, but I haven’t chosen one yet because the markets are so volatile,” she said.

Ms Allfrey said she and her WaveStone colleagues, including co-founder Raaz Bhuyan, were “frustrated” during the recent bull market seeing speculative companies were fetching high prices.

“We got very frustrated after Covid when interest rates went to zero. The stock prices of non-profitable companies, which we don’t invest in, went to the moon,” she said. “It was just ridiculous. But now that has been reversed, it has been fabulous. Now we have a cost of capital and a valuation discipline back in the market, which is really pleasing to see.”

Ms Allfrey said the pandemic changed the landscape for some companies in Australia, such as Qantas, which she says emerged from Covid-19 in a much stronger position in the market.

“Rule one of investing is never own an airline,” she said. “Rule two is don’t ignore rule one.”

But Qantas has bounced back strongly from the pandemic with increased market share, which will continue at least into the medium term while Virgin Australia, now in the hands of private equity, is focused on profitability, she said.

Ms Allfrey sees ResMed as another stock which has also come through Covid-19 well – one with more upside if it can get through issues with its supply chain.

When Ms Allfrey and her colleagues were setting up shop, they originally went with WaterStone.

But they got an irate email from a US hedge fund of the same name ordering them to drop the name. “When we got a second one we hurriedly changed the name,” she said. “But they didn’t survive the GFC and we are still here.”

 

 

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 17 October 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Investors should brace for a string of profit downgrades as the global economic downturn hits Australia somewhere between early ­December and February.

That’s the view of WaveStone Capital director Catherine Allfrey, who says that corporates are in a twilight zone between the difficult times later this year and the strong earnings from the bounce out of the Covid-19 pandemic.

“We are waiting for the profit downgrades to come through in the US and Australia,” she said in an interview with The Australian.

“Rates are going to go up and consumption is going to be hit. It’s a question of when that is going to happen. Everyone knows the slowdown is coming,” she said.

“When we ask companies when they think it is going to happen, their answers range from early December to the back-to-school period in February.”

Ms Allfrey was speaking ahead of her first appearance at the annual Sohn Hearts & Minds investment conference to be held in Hobart in November.

The Sohn conference, which sees top fund managers give their stock tips, has raised more than $40m for medical research since it began in Australia in 2016, inspired by a similar event started in New York in 1995 in memory of Wall Street fund manager Ira Sohn, who died of cancer aged 29.

Ms Allfrey says her stock tip would be in line with the investment approach at WaveStone, which she co-founded in 2006, of looking for “quality companies with a sustainable competitive ­advantage at a reasonable price”.

“We have a very tight process (of stock selection),” she says. “We are value orientated.”

WaveStone, which is 32.5 per cent owned by the ASX-listed Challenger Group, has some $5bn in funds under management, $1bn in retail investment and another $4bn invested on behalf of super fund and institutional investors.

It invests in Australian companies and they must be profitable or expect to be within 12 months. The portfolio includes Qantas, ResMed, Woodside, Santos, CSL, Carsales and Aristocrat.

In selecting her stock tip, Ms Allfrey says she will also keep in mind Sohn’s preference for talking about companies that are seen as disruptive. “I’m looking at a few candidates, but I haven’t chosen one yet because the markets are so volatile,” she said.

Ms Allfrey said she and her WaveStone colleagues, including co-founder Raaz Bhuyan, were “frustrated” during the recent bull market seeing speculative companies were fetching high prices.

“We got very frustrated after Covid when interest rates went to zero. The stock prices of non-profitable companies, which we don’t invest in, went to the moon,” she said. “It was just ridiculous. But now that has been reversed, it has been fabulous. Now we have a cost of capital and a valuation discipline back in the market, which is really pleasing to see.”

Ms Allfrey said the pandemic changed the landscape for some companies in Australia, such as Qantas, which she says emerged from Covid-19 in a much stronger position in the market.

“Rule one of investing is never own an airline,” she said. “Rule two is don’t ignore rule one.”

But Qantas has bounced back strongly from the pandemic with increased market share, which will continue at least into the medium term while Virgin Australia, now in the hands of private equity, is focused on profitability, she said.

Ms Allfrey sees ResMed as another stock which has also come through Covid-19 well – one with more upside if it can get through issues with its supply chain.

When Ms Allfrey and her colleagues were setting up shop, they originally went with WaterStone.

But they got an irate email from a US hedge fund of the same name ordering them to drop the name. “When we got a second one we hurriedly changed the name,” she said. “But they didn’t survive the GFC and we are still here.”

 

 

This article was originally posted by The Australian here.

Licensed by Copyright Agency. You must not copy this work without permission.

Disclaimer: This material has been prepared by The Australian, published on 17 October 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

Disclaimer: This material has been prepared by The Australian, published on Oct 17, 2022. HM1 is not responsible for the content of linked websites or content prepared by third party. The inclusion of these links and third-party content does not in any way imply any form of endorsement by HM1 of the products or services provided by persons or organisations who are responsible for the linked websites and third-party content. This information is for general information only and does not consider the objectives, financial situation or needs of any person. Before making an investment decision, you should read the relevant disclosure document (if appropriate) and seek professional advice to determine whether the investment and information is suitable for you.

facebook
linkedin
All
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
March 14, 2025

$1.4 million boost for SA medical research

South Australian medical research will receive a $1.4 million cash injection, as a direct result of a major investment and philanthropy conference held in Adelaide.

Read More
Anthony Scaramucci’s time in the White House was brief but memorable. APAnthony Scaramucci’s time in the White House was brief but memorable. APAnthony Scaramucci’s time in the White House was brief but memorable. APAnthony Scaramucci’s time in the White House was brief but memorable. AP
May 19, 2025

Why ‘The Mooch’ thinks Trump is more dangerous this time around

Anthony Scaramucci says Trump has fewer constraints on his worst instincts in his second administration. But he still gets bored easily.

Read More
Image caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn LichtImage caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn LichtImage caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn LichtImage caption: Anthony “The Mooch” Scaramucci at the New York headquarters of his SkyBridge Capital last week. Picture: Jaclyn Licht
May 19, 2025

My biggest mistake: Anthony Scaramucci on what makes Donald Trump tick

On Elon Musk, money and the White House, fast-talking Wall Street hedge fund manager and former Trump communications director Anthony Scaramucci tells it as he sees it.

Read More
A bull case for Bitcoin even as it trades near record levels. Picture: AFPA bull case for Bitcoin even as it trades near record levels. Picture: AFPA bull case for Bitcoin even as it trades near record levels. Picture: AFPA bull case for Bitcoin even as it trades near record levels. Picture: AFP
May 19, 2025

Bitcoin ‘on track’ for $US200,000: Anthony Scaramucci

Bitcoin could hit as much as $US200,000 ($311,000) by the end of this year, fuelled by surging inflows into exchange-traded funds and Donald Trump’s erratic policymaking.

Read More
Anthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn LichtAnthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn LichtAnthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn LichtAnthony Scaramucci says America has no choice but to lower tariffs on China further. Jaclyn Licht
May 19, 2025

‘The Mooch’ says Trump will have to cut China tariffs below 10pc

Scaramucci, who is best known as The Mooch, is the first big-name global investor to be confirmed for the Sohn Hearts & Minds conference in Sydney in November.

Read More
Matthew McLennan in his office at First Eagle Investments in New York. Picture: Jaclyn LichtMatthew McLennan in his office at First Eagle Investments in New York. Picture: Jaclyn LichtMatthew McLennan in his office at First Eagle Investments in New York. Picture: Jaclyn LichtMatthew McLennan in his office at First Eagle Investments in New York. Picture: Jaclyn Licht
July 7, 2025

A golden year for Wall Street’s Australian stock picker

Matthew McLennan’s $14.5 billion position in gold bars and miners paid off handsomely for First Eagle this year. But he insists the precious metal still has room to run.

Read More
Stillpoint Investments founder and chief investment officer Eric Wong. Picture: Jaclyn LichtStillpoint Investments founder and chief investment officer Eric Wong. Picture: Jaclyn LichtStillpoint Investments founder and chief investment officer Eric Wong. Picture: Jaclyn LichtStillpoint Investments founder and chief investment officer Eric Wong. Picture: Jaclyn Licht
September 25, 2025

Stillpoint founder Eric Wong reveals major China tech investment strategy

Eric Wong will present his investment case at the Sohn Hearts & Minds conference at the Sydney Opera House on Friday, November 14.

Read More
October 1, 2025

Billionaire hedge fund manager enacts ‘little short’ on the market

Investing veteran Lord Michael Hintze says he’s taking out insurance against expensive debt and equity markets that are being propelled by passive flows.

Read More
October 1, 2025

Hedge fund guru Michael Hintze can't out-trade machines but he can still 'out-invest' them

Billionaire hedge fund manager Michael Hintze says the world is more dangerous than he has ever seen, artificial intelligence is stifling people’s ability to learn and process information.

Read More
Marathon Resource Advisors founder and chief investment officer Robert Mullin in San Francisco.Marathon Resource Advisors founder and chief investment officer Robert Mullin in San Francisco.Marathon Resource Advisors founder and chief investment officer Robert Mullin in San Francisco.Marathon Resource Advisors founder and chief investment officer Robert Mullin in San Francisco.
October 5, 2025

Marathon CIO Robert Mullin reveals why gold stocks are still undervalued

The son of a stockbroker, Mr Mullin has more than 30 years' investing experience and is chief investment officer at Marathon Resource Advisors in San Francisco, a company he founded.

Read More
First Eagle Investments co-head of global value Matthew McLennan. Picture: Jaclyn LichtFirst Eagle Investments co-head of global value Matthew McLennan. Picture: Jaclyn LichtFirst Eagle Investments co-head of global value Matthew McLennan. Picture: Jaclyn LichtFirst Eagle Investments co-head of global value Matthew McLennan. Picture: Jaclyn Licht
October 6, 2025

First Eagle’s Matthew McLennan on the monetary force that could be ‘rocket fuel’ for the Australian dollar

Matthew McLennan, the co-head of the global value team and portfolio manager at the $US161bn ($243bn) First Eagle Investments, stormed the market with a bullish bet on gold.

Read More
October 10, 2025

Anthony Scaramucci’s advice to our PM is to seek his Canadian counterpart’s counsel

Beyond Wall Street, The Mooch is better known for his cutting takes on US politics in the popular podcast The Rest is Politics: US, which he hosts with BBC’s long-term North American correspondent Katty Kay.

Read More
October 19, 2025

Munro Partners' Qiao Ma reveals AI investment strategy

Qiao Ma has a simple test for spotting the investment opportunities that will define the next decade. Take the technology apart and see what’s inside.

Read More
October 21, 2025

Meet the 2025 Conference Managers

Following a global search, the Conference Fund Manager Selection Committee is pleased to share ten new managers for 2025.

Read More
October 31, 2025

The 42pc gain that shows why Sohn is a stock picker’s delight

It turns out you could have outperformed the seemingly unstoppable magnificent seven tech stocks if you simply acted on the 11 stock picks at Sohn last year.

Read More
December 10, 2024

Professor Jane Butler: Sparking Hope for Spinal Cord Injuries

In this episode of the Hearts & Minds Podcast, we sit down with Professor Jane Butler to discuss her groundbreaking research into spinal cord injuries.

Read More
impact-podcasts
September 24, 2024

Asian Market Potential with Tom Naughton of Prusik

CIO Charlie Lanchester sits down with Tom Naughton, CIO of Prusik Investment Mgmt. Tom shares his investment philosophy, the opportunities and challenges in Asian markets, and how his 2023 conference stock pick, Swire Pacific (0019.HK), delivered an impressive 30% return.

Read More
investing
September 4, 2024

Building Hearts and Minds with Co-Founders Matthew Grounds and Guy Fowler

In this episode, co-founders Matthew Grounds AM and Guy Fowler OAM discuss their journey in building Hearts & Minds and its philanthropic model that has donated over $70 million to medical research.

Read More
investing
June 25, 2024

Navigating the Resource Sector with Jeremy Bond of Terra Capital

In this episode, we chat with Jeremy Bond, Founder of Terra Capital and HM1 Conference Fund Manager. Tune in for insights into the world of resource investments and the exciting opportunities that lie ahead.

Read More
investing
June 11, 2024

Prof. Nadia Badawi on Cerebral Palsy Breakthroughs and Neonatal Care

Dive deep into the groundbreaking work of Professor Nadia Badawi, an internationally recognised neonatologist and expert in Cerebral Palsy.

Read More
impact-podcasts
May 28, 2024

Investment Insights: Rikki Bannan on Top Picks and Trends

Join us for an engaging episode featuring Rikki Bannan, Portfolio Manager of IFM Investors and HM1 Conference Fund Manager. This episode explores Rikki's career journey, investment strategies, and her 2023 conference stock pick, Telix Pharmaceuticals (ASX.TLX).

Read More
investing
December 6, 2023

Peter Cooper talks building and instilling a culture of humility and excellence

In this episode, our guest is the renowned investor, Peter Cooper, founder and Chief Investment Officer of Cooper Investors (Core Fund Manager). A founding supporter of Hearts and Minds, Peter is a staunch advocate of our model and its philanthropic purpose, actively engaging in every facet of Hearts and Minds.

Read More
investing
November 28, 2023

Jun Bei Liu on her high conviction investment strategy

In this episode, HM1 Chief Investment Officer Charlie Lanchester is joined by Jun Bei Liu. Jun Bei is the Portfolio Manager of Tribeca’s Alpha Plus Fund and since taking over managing the Fund, she has quadrupled AUM.

Read More
investing
November 21, 2023

The world of rare genetic disease research

In this episode, we speak to Associate Professor Gina Ravenscroft. Gina is an Associate Professor in Neurogenetics at the Harry Perkins Institute of Medical Research in Perth. Her research interests are in rare genetic diseases, with a particular focus on neurogenetic diseases in babies and children.

Read More
impact-podcasts
November 14, 2023

Learn what makes a high conviction investment and how to avoid short-term noise

In this episode, our Core Fund Manager Magellan shares how they select top stocks for the HM1 portfolio.

Read More
investing
November 7, 2023

Delve into the world of kids critical care and trauma research

In thie episode, we are joined by Dr. Marino Festa, or Rino for short. He is the Medical Director of NSW Kids ECMO Referral Service and a senior specialist in Paediatric Intensive Care at Children’s Hospital at Westmead.

Read More
impact-podcasts
October 31, 2023

Where Regal's Phil King is searching for opportunities

HM1's CIO, Charlie Lanchester, talks to Phil King of Regal Funds about his passion for stocks, his ongoing search for opportunities, and some of the sectors he’s excited by right now. Phil King of Regal Funds, has been a tremendous supporter of Hearts & Minds since the beginning.

Read More
investing
October 24, 2023

Preventing recurrent miscarriages and birth defects

In this episode, CEO Paul Rayson is joined by renowned biomedical researcher Professor Sally Dunwoodie. Prof. Dunwoodie's groundbreaking work has revolutionised clinical practices and enabled genetic diagnostic tests worldwide. In 2017, her team achieved a double breakthrough with the potential to prevent recurrent miscarriages and various birth defects.

Read More
impact-podcasts
October 17, 2023

Nick Griffin on how he finds global winners

In this episode, CIO Charlie Lanchester chats with Nick Griffin, the founding partner and CIO of Munro Partners, one of HM1's Core Fund Managers. They go over his career to date, reflect on the lessons he’s learned, and trace the decisions that led to him starting Munro.

Read More
investing
October 10, 2023

How A/Prof Matt Call is teaching our body to kill cancer

In this episode, CEO Paul Rayson is joined by WEHI’s Associate Professor Matt Call to talk about his incredible research. Matt’s team teaches and trains the body's own immune cells to target and kill cancer cells.

Read More
impact-podcasts

No results found.

Please try a different search keyword or filter.